| Ms Elise Steele, | |
|
2550 Bell Rd, Auburn, CA 95603-2502 | |
| (530) 401-9979 | |
| (530) 401-9966 |
| Full Name | Ms Elise Steele |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 2550 Bell Rd, Auburn, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407157712 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 35518 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Elise Steele, 2550 Bell Rd, Auburn, CA 95603-2502 Ph: () - | Ms Elise Steele, 2550 Bell Rd, Auburn, CA 95603-2502 Ph: (530) 401-9979 |
News Archive
BioDelivery Sciences International, Inc. announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating frontline clinicians who are faced with treating patients with pain. The presentation will take place on Friday, September 10, as part of the 7:00 - 9:00 AM podium presentation session.
Fletcher-Flora Health Care Systems, Inc. announced today the availability of FFlex ePortal Outreach solution. FFlex ePortal is a comprehensive laboratory outreach solution for healthcare facilities, including hospitals, large or small, reference labs, physician offices, nursing homes, clinics or any other facility that requires secure remote access to patient lab data.
People who are free of dementia and have high levels of a protein that indicates the presence of inflammation have relatives who are more likely to avoid the disease as well, according to a new study published in the August 15, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.
A breast cancer treatment based on MIT radar research that was originally aimed at detecting space-borne missiles is showing promise in the final phase of clinical testing.
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.
› Verified 4 days ago
John Frank Ayres, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2805 Bell Rd, Auburn, CA 95603 Phone: 530-823-8125 Fax: 530-823-8179 | |
Thuong Hoang, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2700 Bell Rd # 95603, Auburn, CA 95603 Phone: 530-889-5650 | |
Da Kang, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 388 Elm Ave, Auburn, CA 95603 Phone: 530-823-0825 | |
May Goto, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2700 Bell Rd, Auburn, CA 95603 Phone: 530-889-2766 | |
Janine Mary Hackland, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 420 Grass Valley Hwy, Auburn, CA 95603 Phone: 530-823-0558 | |
Yvonne Chih Cunningham, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2550 Bell Rd, Auburn, CA 95603 Phone: 530-401-9979 | |
Viktoriya Ioffe, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12120 New Airport Rd, Auburn, CA 95603 Phone: 530-888-9235 |